The kynurenine pathway (KP), the major catabolic route of tryptophan in mammals, contains several neuroactive metabolites, including kynurenic acid (KYNA) and 3-hydroxykynurenine (3-HK). KP metabolism, and especially the fate of KYNA, during pregnancy is poorly understood, yet it may play a significant role in the development of psychiatric disorders later in life. The present study was designed to investigate the prenatal features of KP metabolism in vivo, with special focus on KYNA. To this end, pregnant CD-1 mice were treated systemically with kynurenine (100 mg/kg), KYNA (10 mg/kg), or saline on embryonic day 18. As expected, administration of either kynurenine or KYNA increased KYNA levels in the maternal plasma and placenta. Maternal kynurenine treatment also raised kynurenine levels in the fetal plasma and brain, demonstrating the ability of this pivotal KP metabolite to cross the placenta and increase the levels of both KYNA and 3-HK in the fetal brain. In contrast, maternal administration of KYNA caused only a small, nonsignificant elevation in KYNA levels in fetal plasma and brain. Complementary experiments using an ex vivo placental perfusion procedure confirmed the significant transplacental transfer of kynurenine and demonstrated that only a very small fraction of maternal kynurenine is converted to KYNA in the placenta and released into the fetal compartment under physiological conditions. Jointly, these results help to clarify the contributions of the maternal circulation and the placenta to fetal KYNA in the late prenatal period.

Keywords:
3-Hydroxykynurenine, Neurodevelopment, Placenta, Schizophrenia
1.
Perkins MN, Stone TW: An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 1982;247:184-187.
2.
Foster AC, Vezzani A, French ED, Schwarcz R: Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 1984;48:273-278.
3.
Guidetti P, Schwarcz R: 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 1999;11:3857-3863.
4.
Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ: Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012;13:465-477.
5.
Badawy AA: Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res 2017;10:1178646917691938.
6.
Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC: Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001;50:521-530.
7.
Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, Schwarcz R: Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 2011;37:1147-1156.
8.
Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G: Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001;313:96-98.
9.
Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, Samuelsson M, Erhardt S: Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012;38:426-432.
10.
Fatemi SH, Folsom TD: The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009;35:528-548.
11.
Owen MJ, O'Donovan MC, Thapar A, Craddock N: Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry 2011;198:173-175.
12.
Rapoport JL, Giedd JN, Gogtay N: Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 2012;17:1228-1238.
13.
Pocivavsek A, Wu HQ, Elmer GI, Bruno JP, Schwarcz R: Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci 2012;35:1605-1612.
14.
Pocivavsek A, Thomas MA, Elmer GI, Bruno JP, Schwarcz R: Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology (Berl) 2014;231:2799-2809.
15.
Forrest CM, McNair K, Pisar M, Khalil OS, Darlington LG, Stone TW: Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine. Neuroscience 2015;310:91-105.
16.
Pershing ML, Bortz DM, Pocivavsek A, Fredericks PJ, Jorgensen CV, Vunck SA, Leuner B, Schwarcz R, Bruno JP: Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia. Neuropharmacology 2015;90:33-41.
17.
Beal MF, Swartz KJ, Isacson O: Developmental changes in brain kynurenic acid concentrations. Brain Res Dev Brain Res 1992;68:136-139.
18.
Ceresoli-Borroni G, Schwarcz R: Perinatal kynurenine pathway metabolism in the normal and asphyctic rat brain. Amino Acids 2000;19:311-323.
19.
Cannazza G, Chiarugi A, Parenti C, Zanoli P, Baraldi M: Changes in kynurenic, anthranilic, and quinolinic acid concentrations in rat brain tissue during development. Neurochem Res 2001;26:511-514.
20.
Walker DW, Curtis B, Lacey B, Nitsos I: Kynurenic acid in brain and cerebrospinal fluid of fetal, newborn, and adult sheep and effects of placental embolization. Pediatr Res 1999;45:820-826.
21.
Ligam P, Manuelpillai U, Wallace EM, Walker D: Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy. Placenta 2005;26:498-504.
22.
Manuelpillai U, Ligam P, Smythe G, Wallace EM, Hirst J, Walker DW: Identification of kynurenine pathway enzyme mRNAs and metabolites in human placenta: up-regulation by inflammatory stimuli and with clinical infection. Am J Obstet Gynecol 2005;192:280-288.
23.
Murthi P, Wallace EM, Walker DW: Altered placental tryptophan metabolic pathway in human fetal growth restriction. Placenta 2017;52:62-70.
24.
Milart P, Urbanska EM, Turski WA, Paszkowski T, Sikorski R: Kynurenine aminotransferase I activity in human placenta. Placenta 2001;22:259-261.
25.
Beggiato S, Sathyasaikumar KV, Notarangelo FM, Giorgini F, Muchowski PJ, Schwarcz R: Prenatal kynurenine treatment in mice: effects on placental and fetal brain kynurenines. Soci Neurosci Abstr 2014;39:51.09.
26.
Notarangelo FM, Schwarcz R: Restraint stress during pregnancy rapidly raises kynurenic acid levels in mouse placenta and fetal brain. Dev Neurosci 2016;38:458-468.
27.
Nugent BM, Bale TL: The omniscient placenta: metabolic and epigenetic regulation of fetal programming. Front Neuroendocrinol 2015;39:28-37.
28.
Bonnin A, Goeden N, Chen K, Wilson ML, King J, Shih JC, Blakely RD, Deneris ES, Levitt P: A transient placental source of serotonin for the fetal forebrain. Nature 2011;472:347-350.
29.
Ewald RC, Cline HT: NMDA receptors and brain development; in Van Dongen AM (ed): Biology of the NMDA Receptor. Boca Raton, CRC Press/Taylor & Francis, 2009.
30.
Zheng JQ, Felder M, Connor JA, Poo MM: Turning of nerve growth cones induced by neurotransmitters. Nature 1994;368:140-144.
31.
Goeden N, Bonnin A: Ex vivo perfusion of mid-to-late-gestation mouse placenta for maternal-fetal interaction studies during pregnancy. Nat Protoc 2013;8:66-74.
32.
Nicholls T, Nitsos I, Walker DW: Tryptophan metabolism in pregnant sheep: increased fetal kynurenine production in response to maternal tryptophan loading. Am J Obstet Gynecol 1999;181:1452-1460.
33.
Ceresoli-Borroni G, Guidetti P, Amori L, Pellicciari R, Schwarcz R: Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J Neurosci Res 2007;85:845-854.
34.
Challier JC, D'Athis P, Guerre-Millo M, Nandakumaran M: Flow-dependent transfer of antipyrine in the human placenta in vitro. Reprod Nutr Dev 1983;23:41-50.
35.
Heikkine T, Ekblad U, Laine K: Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. BJOG 2002;109:1003-1008.
36.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
37.
Morita I, Kawamoto M, Yoshida H: Difference in the concentration of tryptophan metabolites between maternal and umbilical foetal blood. J Chromatogr 1992;576:334-339.
38.
Tsuji A, Nakata C, Sano M, Fukuwatari T, Shibata K: L-Tryptophan metabolism in pregnant mice fed a high L-tryptophan diet and the effect on maternal, placental, and fetal growth. Int J Tryptophan Res 2013;6:21-33.
39.
Rennie MY, Mu J, Rahman A, Qu D, Whiteley KJ, Sled JG, Adamson SL: The Ultraplacental, Fetoplacental, and Yolk Sac Circulation in the Mouse. San Diego, Elsevier, 2014, pp 201-210.
40.
Ganapathy ME, Leibach FH, Mahesh VB, Howard JC, Devoe LD, Ganapathy V: Characterization of tryptophan transport in human placental brush-border membrane vesicles. Biochem J 1986;238:201-208.
41.
Beggiato S, Notarangelo FM, Schwarcz R: Maternal, placental and fetal KYNA production in mouse tissue slices. Soc Neurosci Abstr 2015;40:48.19.
42.
Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR: Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991;56:2007-2017.
43.
Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R: On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem 2009;109:316-325.
44.
Chen Y, Guillemin GJ: Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009;2:1-19.
45.
Mangge H, Summers KL, Meinitzer A, Zelzer S, Almer G, Prassl R, Schnedl WJ, Reininghaus E, Paulmichl K, Weghuber D, Fuchs D: Obesity-related dysregulation of the tryptophan-kynurenine metabolism: role of age and parameters of the metabolic syndrome. Obesity (Silver Spring) 2014;22:195-201.
46.
Notarangelo FM, Wilson EH, Horning KJ, Thomas MA, Harris TH, Fang Q, Hunter CA, Schwarcz R: Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. Schizophr Res 2014;152:261-267.
47.
Zavitsanou K, Lim CK, Purves-Tyson T, Karl T, Kassiou M, Banister SD, Guillemin GJ, Weickert CS: Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition. Brain Behav Immun 2014;41:173-181.
48.
Nicholls T, Nitsos I, Smythe G, Walker DW: Kynurenine production and catabolism in fetal sheep with embolized or nonembolized placentas. Am J Obstet Gynecol 2001;185:988-995.
49.
Hsiao EY, Patterson PH: Placental regulation of maternal-fetal interactions and brain development. Dev Neurobiol 2012;72:1317-1326.
50.
Goeden N, Velasquez J, Arnold KA, Chan Y, Lund BT, Anderson GM, Bonnin A: Maternal inflammation disrupts fetal neurodevelopment via increased placental output of serotonin to the fetal brain. J Neurosci 2016;36:6041-6049.
51.
Notarangelo FM, Schwarcz R: Prenatal LPS exposure preferentially increases kynurenine pathway metabolism in the fetal brain. Soc Neurosci Abstr 2015;40:74.02.
52.
Badawy AA: The tryptophan utilization concept in pregnancy. Obstet Gynecol Sci 2014;57:249-259.
53.
Sedlmayr P, Blaschitz A, Stocker R: The role of placental tryptophan catabolism. Front Immunol 2014;5:230.
54.
Forrest CM, Khalil OS, Pisar M, Darlington LG, Stone TW: Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus. Brain Res 2013;1504:1-15.
55.
Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE, Kajii Y, Thaker GK, Schwarcz R: Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011;68:665-674.
56.
Forrest CM, Khalil OS, Pisar M, McNair K, Kornisiuk E, Snitcofsky M, Gonzalez N, Jerusalinsky D, Darlington LG, Stone TW: Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway. Neuroscience 2013;254:241-259.
57.
Khalil OS, Pisar M, Forrest CM, Vincenten MC, Darlington LG, Stone TW: Prenatal inhibition of the kynurenine pathway leads to structural changes in the hippocampus of adult rat offspring. Eur J Neurosci 2014;39:1558-1571.
58.
Pisar M, Forrest CM, Khalil OS, McNair K, Vincenten MC, Qasem S, Darlington LG, Stone TW: Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway. Brain Res 2014;1576:1-17.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.